恩替卡韦抗乙型肝炎病毒的临床观察

目的观察恩替卡韦治疗慢性乙型肝炎的临床疗效。方法49例未经抗病毒治疗的慢性乙型肝炎患者随机分为治疗组和对照组。治疗组25例，口服恩替卡韦片0．5mg／d；对照组24例，口服拉米夫定片100mg／d。在治疗后12周及24周，比较两组患者HBVDNA水平，ALT复常率，血清学标志和安全性方面的情况，对基线时HbeAg（＋）患者比较HBeAg阴转和血清转换。结果治疗12周、24周后治疗组的ALT复常率，HBVDNA的转阴率明显优于对照组，HBeAg的阴转率，两组较为相似。结论恩替卡韦治疗慢性乙型肝炎起效快，是一种安全、有效的新型抗乙型肝炎病毒的药物。

Clinical study of antiviral effects of Entecavir in patients with chronic Hepatitis B

Objective To study the antiviral effects of Entecavir in patients with chronic Hepatitis B. Methods 49 patients with no prior history of antiviral therapy were randomly assigned to receive Entecavir tablet （0. 5 mg） or Lamivudine tablet （ 100 mg） qd. ALT normalization,HBV-DNA level were assessed during the following 12,24 weeks, if HbeAg（ ＋ ）at baseline for HbeAg sero conversion cumulative proportions of all-treated patients who ever achieved these responses were also analyzed. Results After 12 weeks, ALT normaliza- tion, HBV-DNA level in the treat group was significantly higher than in the control group （P 〈 0. 05 ） , there was no difference in two groups for HBeAg sero conversion（ P 〉 0. 05 ） . after 24 weeks, HBeAg sero conversion in the treat group was significantly higher than in the control group （ P 〈 0. 05 ）. Conclusion Entecavir is more effective in inhibiting reproduction of HBV than that of Lamivudine .